IBD & Intestinal Disorders
News
AGA Clinical Practice Guidelines: Pharmacologic treatment of IBS
The pair of new guidelines each explore new, old, and over-the-counter options to help physicians take an individualized approach based on...
News from the FDA/CDC
FDA approves risankizumab (Skyrizi) for Crohn’s disease
Risankizumab is already approved in the United States for the treatment of adults with active psoriatic arthritis and moderate to severe plaque...
Short Clinical Reviews
Endoscopic management of duodenal and ampullary adenomas
EMR in the duodenum is tricky because of its thin muscle layer, increased motility, and significant vascular supply.
From the Journals
Upadacitinib a ‘welcome’ new treatment option for ulcerative colitis
The phase 3 trials randomly assigned 660 patients with moderately to severely active ulcerative colitis to oral upadacitinib 45 mg daily or...
From the Journals
Do myenteric neurons replicate in small intestine?
Researchers sought to replicate a controversial 2017 study, but this time keeping an eye on possible confounding variables.
Sponsored Supplement
Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults
Latest News
Mirikizumab keeps ulcerative colitis at bay without steroids
Patients who responded to mirikizumab at 12 weeks achieved and maintained “statistically superior and clinically meaningful” improvements at 1...
Conference Coverage
Psychological intervention looks promising in Crohn’s disease
A combination of mindfulness and cognitive-behavioral therapy showed promise for pain, fatigue, and productivity associated with Crohn’s.
Conference Coverage
Eosinophilic diseases often overlap, raising costs
Overlap was less common in eosinophilic esophagitis, but more common in eosinophilic gastritis/eosinophilic gastroenteritis.
Conference Coverage
H. pylori antibiotics briefly disrupt gut microbiome
Researchers compared antibiotic resistance following either levofloxacin quadruple therapy or bismuth quadruple therapy.
Conference Coverage
Fidaxomicin favored over vancomycin in real-world C. diff study
Researchers compared the agents for treating both initial and recurrent Clostridioides difficile infections in a Medicare population.